Px HA PEEK IBF System
Device Facts
| Record ID | K151785 |
|---|---|
| Device Name | Px HA PEEK IBF System |
| Applicant | Innovasis, Inc. |
| Product Code | MAX · Orthopedic |
| Decision Date | Oct 14, 2015 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Innovasis Px HA PEEK IBF System is an intervertebral body fusion device intended to stabilize a spinal segment to promote fusion using bone graft, in order to restrict motion and decrease pain. Users of these products are limited to physicians trained in orthopedic surgery. Clinical locations include hospitals and surgery sites equipped to perform spinal surgery. The Innovasis Px HA™ PEEK IBF System is an intervertebral body fusion device for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbar spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to a Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). These implants are used to facilitate fusion in the lumbar spine and are placed via either a posterior (PLIF) or modified transforaminal (T-PLIF) approach. This device is intended to be used in pairs and with internal supplemental spinal fixation systems such as the Innovasis Excella® Spinal System. The interior of the Px HA implant is intended to be packed with autograft.
Device Story
Intervertebral body fusion device; used in pairs via posterior (PLIF) or modified transforaminal (T-PLIF) approach; stabilizes spinal segments to promote fusion. Implants feature open interior cavity for autograft packing; anti-migration teeth engage vertebral endplates; tapered leading edge aids insertion. Radiolucent PEEK-OPTIMA HA Enhanced material allows fusion assessment; tantalum spheres provide radiographic visualization. Used in hospitals/surgery centers by orthopedic surgeons; requires supplemental internal spinal fixation (e.g., Innovasis Excella). Benefits include motion restriction and pain reduction in DDD patients.
Clinical Evidence
Bench testing only. Performance evaluated per ASTM F2077-11 and F2267-04 standards, including static axial compression, dynamic axial compression, torsion, subsidence, and expulsion testing. Testing included simulated aging of devices prior to dynamic mechanical evaluation.
Technological Characteristics
Implants machined from Invibio PEEK-OPTIMA HA Enhanced (PEEK with integrated hydroxyapatite). Radiographic markers are unalloyed Tantalum (ASTM F560). Complies with ASTM F2026 (PEEK), ASTM F2077 (fusion device testing), and ASTM F2267 (subsidence). Sterilization via moist heat (ISO 17665-1). Form factor includes tapered leading edge, anti-migration teeth, and open cavity for bone graft.
Indications for Use
Indicated for skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous lumbar levels (L2-S1), including up to Grade 1 spondylolisthesis or retrolisthesis, who have failed at least six months of non-operative treatment.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
Predicate Devices
- Innovasis Px™ PEEK IBF System (K150500)